Genome_Biology_Submission_Template_2020

1、1sect ionThe template is designed to help the submission of your article. For more detailed information about Genome Biology and its submission guidelines, please go to the journal official website.? Genome Biology homepage? Submissi on guideli nes? Submissi on link: https:/www.editorialma In format

2、i on on fees and funding? If your manu script describes a methodological adva nee or new software tool, please see the in formati on about Method and Software manu scriptsSubmissi on no tes:? Your manu script must in clude a Declarati ons sect ion.? Use double line spac ing, in clude line and page n

3、u mberi ng, do not use page breaks in your manu script ? Use SI units: Please ensure that all special characters used are embedded in the text, otherwise they will be lost duri ng con vers ion to PDF? The Abstract should not exceed 250 words. Please minimize the use of abbreviations and do not cite

4、referen ces in the abstract. The abstract must in clude the followi ng separate secti ons: Backgro und, Results, and Con clusi ons.? The follow ing word processor file formats are acceptable for the main manu script docume nt: Microsoft word (DOC, DOCX) , Rich text format (RTF) , TeX/LaTeX (use BioM

5、ed Centrals TeX template). If a TeX format is submitted, please include a reference PDF of the manuscript.? Note that editable files are required for process ing in product ion.Title PageThe title page should:present a title that includes, if appropriate, the study design, e.g.:o A versus B in the t

6、reatme nt of C: a ran domized con trolled trial, X is a risk factor for Y: a case control study, What is the impact of factor X on subject Y: A systematic reviewo or for non-cli ni cal or non-research studies, a descripti on of what the article reportslist the full names and institutional addresses

7、for all authorso if a collaboration group should be listed as an author, please list the Group name as an author. If you would like the n ames of the in dividual members of the Group to be searchable through their in dividual PubMed records, please in clude thi s in formati on in the“ Ackno wledgeme

8、 nts in accorda nce with the in structi ons belowin dicate the corresp onding author12345678910111213141516171819202122232425262728293031323334352Article TitleFirst name-1 Last name-1. First name-2 Last name-2. First name-3 Last name-3 & First name-4 Last name-4AbstractBackgro undDescribe the con te

9、xt and purpose of the study.ResultsWrite the main findin gs.Con clusi onsPresent a brief summary and potential implications.KeywordsThree to ten keywords representing the main content of the article.BackgroundThe Backgro und secti on should expla in the backgro und to the study, its aims, a summary

10、of the existi ng literature and why this study was necessary or its contribution to the field.ResultsThis sect ion should in clude the findings of the study in cludi ng, if appropriate, results of statisticalanalysis which must be included either in the text or as tables (Table 1) and figures (Fig.1

11、).For details on how to prepare figures, visit here.3637383940414243444546474849505152535455563For additional information on how to prepare tables, visit here.4W 20Conneciliig tubuleFig. 1Comparis on of sin gle-cell and sin gle-n ucleus libraries. a Cell type compositi on for kid neys from Balb/c fe

12、male mice.Average percentages for scRNA-seq libraries are shown in blue and for snRNA-seq libraries in gray. BSEQ-sc estimates are show n for bulk RNA-seq of i ntact and dissociated kid neys. Error bars are sta ndard error of mean, b Abundance of renal epithelial cell types in Clark et al. study 34

13、in comparis on to our data from Balb/c female mice.Table 1 Table title (max 15 words). Lege nd (max 300 words) should be in cluded un der neath the tableCharacteristicsGroup AGroup BGroup A+BGroup C5758596061626364656667Dtsioc4idd k) )dMySjngile-gOSN FA隔 3w500gSN FANS iOOCg3N sucrosAfinlact 3 w DrsE

14、ociated kidney Sjngio-Gflii SN FANS SxbOOg SN_F4NS_i200Cg &N UCTQ&eIrr munft Mt0 4JD 0L QQQ of HiftnlfiQ 510 1S 2DMesangiumEnrthvli 刖Olrtnr klbUteE：Loop of HerileRxkscyfce0 1 2Clark ot al.Intact fedne 口诘鈕抽甜kid档 S-iTglecell 百inl白 Tiue伯 umlstai ranvoiuted Wbuiea 24 e aCal IT电qs色PToKirnal iutKile5Age (

15、years)3.0 (0.9 -.5)1.0 (1.0 -4.5)1.0 (1.0 -4.5)1.0 (1.0 -4.5 2.522/43 (51%)21/43 (49%)21/43 (49%)21/43 (49%) ?2.521/43 (49%)4/7 (57%)4/7 (57%)4/7 (57%)Sexmale23/43 (53%)5/7 (71%)5/7 (71%)5/7 (71%)female20/43 (47%)2/7 (29%)2/7 (29%)2/7 (29%)Cli nical statusAsymptomatic a0/43 (0%)2/7 (29%)2/50 (4%)0/2

16、6 (0%)Very mild0/43 (0%)5/7 (71%)5/50 (10%)0/26 (0%)Mild41/43 (95%)0/7 (0%)41/50 (82%)26/26 (100% )Severe0/43 (0%)0/7 (0%)0/50 (0%)0/26 (0%)Critically ill2/43 (5%)0/7 (0%)2/50 (4%)0/26 (0%)SymptomsFever29/43 (67%)3/7 (43%)32/50 (64%)21/26 (81%)Cough21/43 (49%)1/7 (14%)22/50 (44%)|19/26 (73%)Myalgia/

17、fatigue2/43 (5%)0/7 (0%)2/50 (4%)0/26 (0%)Sore throat1/43 (2%)0/7 (0%)1/50 (2%)0/26 (0%)Diarrhea3/43 (7%)0/7 (0%)3/50 (6%)0/26 (0%)aNo cli ni cal symptoms and no abno rmal CT findingsResults that would otherwise be in dicated as data not show n should be in cluded as additi onal files.BioMed Central

18、 requires that supporting data are included as additional files or deposited in a recognized repository. The maximum file size for additional files is recommended as 20 MB each. Each additional file should be cited in sequence within the main body of text. For more information on additional files, v

19、isit: here.Discussi onFor research articles, this secti on should discuss the implicati ons of the findings in the con text of existi ng research and highlight limitations of the study. For study protocols and methodology manuscripts, this sect ion should in clude a discussi on of any practical or o

20、perati onal issues in volved in perform ing the study and any issues not covered in other secti ons.Con clusi onsThis should state clearly the main conclusions and provide an explanation of the importance and releva nce of the study to the field.6869707172737475767778798081826MethodsThe methods sect

21、i on should in elude:? the aim, desig n and sett ing of the study,? the characteristics of participa nts or descripti on of materials,?a clear descripti on of all processes, in terve nti ons, and comparis ons. Gen eric drug n ames shouldgen erally be used. Whe n proprietary brands are used in resear

22、ch, in clude the brand n ames in pare ntheses,? the type of statistical analysis used, including a power calculation if appropriate.ReferencesExamples of the Vancouver reference style are shown here. All web links and URLs, including links to the authors own websites, should be give n a reference nu

23、 mber and be in cluded in the reference list rather than withi n the text of the manu script.DeclarationsAll manu scripts must contain the follow ing secti ons un der the headi ng Declarati on s: Ethics approval and consent to participate, Consent for publication, Availability of data and materials,

24、 Competing interests, Funding, Authors con tributi ons, Ackno wledgeme nts, and Authors in formati on (opti on al). If any of the sect ions are not releva nt to your manu script, please in clude the headi ng and write Not applicable for that sect ion.Ethics approval and consent to participateManu sc

25、ripts report ing studies in volv ing huma n participa nts, huma n data or huma n tissue, a stateme nt must be in cluded that writte n consent was give n from all participa nts and also a stateme nt that the experime ntal methods comply with the Helsi nki Declarati on.83848586878889909192939495969798

26、991001011021031047? in elude a stateme nt on ethics approval and consen t (eve n where the n eed for approval was waived)? include the name of the ethics committee that approved the study and the committee s referencnu mber if appropriateStudies involving animals must include a statement on ethics a

27、pproval and for experimental studies in volvi ng clie nt-ow ned ani mals, authors must also in clude a stateme nt on in formed consent from the clie nt or own er. For more in formatio n, visit here.Consent for publicatio nIf your manu script con tai ns any in dividual pers on s data in any form (in

28、cludi ng any in dividual details,images or videos), consent for publicati on must be obta ined from that pers on, or in the case of childre n, their pare nt or legal guardia n. All prese ntati ons of case reports must have consent for publicati on.You can use your institutional consent form or our c

29、onsent form if you prefer. You should not send the form to us on submissi on, but we may request to see a copy at any stage (in cludi ng after publicati on).For more information on consent for publication, visit here.Availability of data and materialsAll manu scripts must in clude an Availability of

30、 data and materials stateme nt. Data availabilitystatements should include information on where data supporting the results reported in the article can be found in cludi ng, where applicable, hyperli nks to publicly archived datasets an alysed or gen erated dur ing the study. We recog nise it is not

31、 always possible to share research data publicly, for in sta nee whe n in dividual privacy could be compromised, and in such in sta nces data availability should still be stated in the manuscript along with any conditions for access. If your manuscript does not contain any data, please state Not app

32、licable in this sect ion. For more in formatio n, visit: hereCompet ing in terests1051061071081091101111121131141151161171181191201211221231241251268All financial and non-financial competing interests must be declared in this section.See our editorial policies for a full explanation of competing int

33、erests. If you are unsure whether you or any of your co-authors have a competi ng in terest, please con tact the editorial office.Please use the authors initials to refer to each authors competing interests in this section.If you do not have any competing interests, please state The authors declare

34、that they have no competing interests in this section.FundingAll sources of funding for the research reported should be declared. The role of the funding body in the desig n of the study and collect ion, an alysis, and in terpretati on of data and in writ ing the manu script should be declared.Autho

35、rs InformationYou may choose to use this sect ion to in clude any releva nt in formati on about the author(s) that may aid the readers interpretation of the article and understand the standpoint of the author(s). This may include details about the authors qualifications, current positions they hold

36、at institutions or societies, or any other releva nt backgro und in formati on. Please refer to authors using their in itials. Note this secti on should not be used to describe any compet ing in terests.Affiliatio nsSchool of Engin eeri ng and Material Science, Quee n Mary Uni versity of London, Lon

37、don, UKFirst namel nitials-1 Last name-1 , First namel nitials-2 Last name-2 & First namel nitials-3 Last name -3Process & Energy Department, Faculty of Mechanical, Maritime and Materials Engineering, DelftUn iversity of Tech no logy, Delft, The Netherla ndsFirst namel nitials-4 Last name -4Con tributi ons1271281291301311321331341351361371381391401411421431441451461471481491509The in dividual con tributi ons of authors to the manu script should be specified in this sect ion. Please use in itials to refer to each authors con tributi on in this sect ion, for example: FC an alyzed and